A
Albert Mimran
Researcher at University of Montpellier
Publications - 153
Citations - 4611
Albert Mimran is an academic researcher from University of Montpellier. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 31, co-authored 153 publications receiving 4432 citations.
Papers
More filters
Journal ArticleDOI
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller,Sadayoshi Ito,Joseph L. Izzo,Andrzej Januszewicz,Shigehiro Katayama,Jan Menne,Albert Mimran,Ton J. Rabelink,Eberhard Ritz,Luis M. Ruilope,Lars Christian Rump,Giancarlo Viberti +11 more
TL;DR: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
Journal ArticleDOI
Combined renal effects of overweight and hypertension.
TL;DR: The results indicate that the overweight condition is associated with renal hyperfiltration and hyperperfusion, irrespective of the presence of hypertension, and that obesity magnifies the effect of hypertension on albuminuria, thus raising the possibility of an increased susceptibility of obese hypertensive patients to the development of renal damage.
Journal ArticleDOI
The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
Victor J. Dzau,Kenneth E. Bernstein,David S. Celermajer,Jerome D. Cohen,Jerome D. Cohen,Björn Dahlöf,John Deanfield,Javier Diez,Helmut Drexler,Roberto Ferrari,Wiek H. van Gilst,Lennart Hansson,Burkhard Hornig,Ahsan Husain,Colin I. Johnston,Harold L. Lazar,Eva Lonn,Thomas F. Lüscher,John Mancini,Albert Mimran,Carl J. Pepine,Ton J. Rabelink,Willem J. Remme,Luis M. Ruilope,Marcel Ruzicka,Heribert Schunkert,Karl Swedberg,Thomas Unger,Douglas E. Vaughan,Michael A. Weber +29 more
TL;DR: Clinical studies comparing the effects of antihypertensives on endothelial function suggest differences and Pharmacokinetic properties of various ACE inhibitors indicate that there are differences in their binding characteristics for tissue ACE.
Journal ArticleDOI
Simvastatin Prevents Angiotensin II–Induced Cardiac Alteration and Oxidative Stress
TL;DR: Results indicate that simvastatin prevented the development of hypertension and cardiovascular hypertrophy together with inhibition of the induced angiotensin II production of ROS.
Journal ArticleDOI
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Victor J. Dzau,Kenneth E. Bernstein,David S. Celermajer,Jerome D. Cohen,Björn Dahlöf,John E. Deanfield,Javier Díez,H.G. Drexler,Roberto Ferrari,W. H. Van Gilst,Lennart Hansson,Burkhard Hornig,Ahsan Husain,Colin I. Johnston,Harold L. Lazar,Eva Lonn,Thomas F. Lüscher,John Mancini,Albert Mimran,Carl J. Pepine,Ton J. Rabelink,W. J. Remme,Luis M. Ruilope,Marcel Ruzicka,Heribert Schunkert,Karl Swedberg,Thomas Unger,Douglas E. Vaughan,Michael A. Weber +28 more
TL;DR: Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined, and that its inhibition may restore endothelial function or prevent endothelial dysfunction.